Presentation Materials for the Fiscal Year Ending March 2026 Results and Medium-Term Management Plan | Qol Holdings Co.,Ltd. (3034) timely disclosure

Worth reading

71In focus

Scored from 5 of 6 sections

Direction

Mixed performance

Direction inferred from the company’s description.

Scale

26799

¥ million (year-on-year increase in consolidated net sales)

Wording

Conditional

How definitive the wording is.

Contents of this document

Presentation materials for financial resultsFiscal year ending March 2026, full year10 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales¥290,772 million+10.2%

Operating profit¥14,811 million+10.0%

Ordinary income¥14,879 million+7.6%

Net income¥7,408 million +43.5%net income attributable to owners of the parent

Selling, general and administrative expenses¥26,090 million

Gross Profit Margin14.1% (gross profit of ¥40,902 million / revenue of ¥290,772 million). Year-on-year change: not disclosed.

Operating profit margin5.1%. Year-on-year change: flat.

Full-year earnings forecast

Fiscal year ending March 2027

Net Sales

¥315,000 million

Operating profit

¥16,500 million

Ordinary income

¥16,500 million

Profit attributable to owners of the parent

¥7,800 million

EBITDA

¥28,700 million

Earnings per share

¥207.76

Annual dividend per share

¥54

What the company explained in this material

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Consolidated

Increase in sales

¥26,799 million

Increase in EBITDA

¥2,797 million

Increase in operating profit

¥1,345 million

Increase in ordinary income

¥1,047 million

Increase in net income

¥2,244 million

Daiichi Sankyo Espha

Increase in sales

200 Hundreds of millions of yen

Increase in operating profit

17 Hundreds of millions of yen

New initiatives

Launch 2 products containing 1 AG active ingredient in June 2026
Plan to launch 2 products containing 1 generic drug active ingredient in the fiscal year ending March 2027
Open new pharmacies and conduct M&A in the pharmacy business, totaling ¥6 billion in annual sales
Expand medical DX, cloud-based electronic medication records, and remote data-entry and remote medication counseling support
Invest in new areas in the pharmaceutical business, including medical devices, medical DTx and products for home-care patients

Key KPIsA metric the company considers important as a management benchmark.

ROE12.9 %
Year on year against the same period last yearUp from 9.4% in the previous year
Shipment volume of key products
Year on year against the same period last year+13%
Weighted average of the Medical DX Promotion System Development Fee8.4 items
Year on year against the same period last year6.7 points in the previous year
Generic drug substitution rate (volume basis)82.6 % March 2026
Year on year against the same period last year89.3% in the previous year

Unit price and quantity metricsThese figures show sales broken down by price and volume.

Pharmacy business

Number of Prescriptions Filled

Existing stores

11,506 thousand prescriptions-3.5%

M&A and other activities

5,055 thousand prescriptions+6.4%

All Stores

16,699 thousand prescriptions-2.2%

Prescription Unit Price

Existing stores

¥10,791+1.3%

M&A and other activities

¥9,481+5.2%

All Stores

¥9,832+5.2%

Segment results

Pharmacy business

Net Sales

¥177,461 million+3.4%

Segment profit

¥9,730 million-3.0%

BPO business

Net Sales

¥14,300 million+5.1%

Segment profit

¥1,898 million+11.3%

Pharmaceutical business

Net Sales

¥99,010 million+25.8%

Segment profit

¥6,960 million+32.0%

Medium-term management plan targets

Target fiscal yearFiscal year ending March 2031

Consolidated revenue

5,000 Hundreds of millions of yen

Compared with the fiscal year ending March 2025+89%

Consolidated operating profit

350 Hundreds of millions of yen

Compared with the fiscal year ending March 2025+160%

ROE

15 %

Comparison with actual results9.4% actual for the fiscal year ended March 2025

Financial targets

ROE

Target15 %

Actual results12.9 %

Fiscal year of actual resultsFiscal year ending March 2026

Number of stores and locations

Number of pharmacy stores

End of period949 Location

During the period

New stores10 Location

M&A9 Location

Concession stand0 Location

Number of pharmacies in technical fee data

March 2025921 Pharmacies

March 2026918 Pharmacies

Annual Dividend

Fiscal year ending March 2026

¥50

Interim23

End of period27

Fiscal year ending March 2027

¥54

Interim27

End of period27

Payout ratio

Fiscal year ending March 202625.3

Fiscal year ending March 202726

Target for the fiscal year ending March 2031More than 30%

Contents of this document
Item	Details
Document type	Presentation materials for financial results
Fiscal Period Covered	Fiscal year ending March 2026, full year
Net Sales	¥290,772 million (YoY +10.2%)
Operating profit	¥14,811 million (YoY +10.0%)
Ordinary income	¥14,879 million (YoY +7.6%)
Net income	¥7,408 million (net income attributable to owners of the parent) (YoY +43.5%)
Gross Profit Margin	14.1% (gross profit of ¥40,902 million / revenue of ¥290,772 million). Year-on-year change: not disclosed.
Operating profit margin	5.1%. Year-on-year change: flat.
Selling, general and administrative expenses	¥26,090 million
Full-year earnings forecast	Subject Fiscal year ending March 2027 / Net Sales ¥315,000 million / Operating profit ¥16,500 million / Ordinary income ¥16,500 million / Profit attributable to owners of the parent ¥7,800 million / EBITDA ¥28,700 million / Earnings per share ¥207.76 / Annual dividend per share ¥54
Segment results	Pharmacy business Net Sales ¥177,461 million (YoY +3.4%) / Segment profit ¥9,730 million (YoY -3.0%) / BPO business Net Sales ¥14,300 million (YoY +5.1%) / Segment profit ¥1,898 million (YoY +11.3%) / Pharmaceutical business Net Sales ¥99,010 million (YoY +25.8%) / Segment profit ¥6,960 million (YoY +32.0%)
Breakdown of Factors Affecting the Change	Consolidated Increase in sales ¥26,799 million / Increase in EBITDA ¥2,797 million / Increase in operating profit ¥1,345 million / Increase in ordinary income ¥1,047 million / Increase in net income ¥2,244 million / Daiichi Sankyo Espha Increase in sales 200 Hundreds of millions of yen / Increase in operating profit 17 Hundreds of millions of yen
Key KPIs	Indicator name ROE / Value 12.9 % / Year on year against the same period last year Up from 9.4% in the previous year, Indicator name Shipment volume of key products / Value Not disclosed / Year on year against the same period last year +13%, Indicator name Weighted average of the Medical DX Promotion System Development Fee / Value 8.4 items / Year on year against the same period last year 6.7 points in the previous year, Indicator name Generic drug substitution rate (volume basis) / Value 82.6 % (March 2026) / Year on year against the same period last year 89.3% in the previous year
Unit price and quantity metrics	Pharmacy business Number of Prescriptions Filled Existing stores 11,506 thousand prescriptions (YoY -3.5%) / M&A and other activities 5,055 thousand prescriptions (YoY +6.4%) / All Stores 16,699 thousand prescriptions (YoY -2.2%) / Prescription Unit Price Existing stores ¥10,791 (YoY +1.3%) / M&A and other activities ¥9,481 (YoY +5.2%) / All Stores ¥9,832 (YoY +5.2%)
Number of stores and locations	Number of pharmacy stores End of period 949 Location / During the period New stores 10 Location / M&A 9 Location / Concession stand 0 Location / Number of pharmacies in technical fee data March 2025 921 Pharmacies / March 2026 918 Pharmacies
Medium-term management plan targets	Target fiscal year Fiscal year ending March 2031 / Consolidated revenue 5,000 Hundreds of millions of yen / Consolidated operating profit 350 Hundreds of millions of yen / ROE 15 %
Financial targets	ROE Target 15 % / Actual results 12.9 % / Fiscal year of actual results Fiscal year ending March 2026 / Equity ratio Not disclosed / ROIC Not disclosed / Debt-to-equity ratio Not disclosed
Annual Dividend	Fiscal year ending March 2026 ¥50 / Fiscal year ending March 2027 ¥54
Payout ratio	Fiscal year ending March 2026 25.3 / Fiscal year ending March 2027 26 / Target for the fiscal year ending March 2031 More than 30%
New initiatives	Launch 2 products containing 1 AG active ingredient in June 2026, Plan to launch 2 products containing 1 generic drug active ingredient in the fiscal year ending March 2027, Open new pharmacies and conduct M&A in the pharmacy business, totaling ¥6 billion in annual sales, Expand medical DX, cloud-based electronic medication records, and remote data-entry and remote medication counseling support, Invest in new areas in the pharmaceutical business, including medical devices, medical DTx and products for home-care patients

Items this document does not state (11)

Results for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Consolidated results benefited from the increase in Daiichi Sankyo Espha's ownership stake from 51% to 80% and the expanded contribution from the pharmaceutical business. In the pharmacy business, the unit price of technical fees increased due to the acquisition of the Medical DX Promotion System Development Fee and a higher generic drug utilization rate, but profit declined. The BPO business benefited from an increase in the number of dispatched medical representatives, while the pharmaceutical business benefited from sales of new products.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.